CII
PTCT icon

CR Intrinsic Investors’s PTC Therapeutics PTCT Stock Holding History

CR Intrinsic Investors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-119,237
Closed -$2.56M – 344
2013
Q3 		$2.56M Buy
+119,237
New +$2.07M 0.08% 268

Other funds holding PTCT

BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

CR Intrinsic Investors's PTCT Position: Q4 2013 in Review

CR Intrinsic Investors sold out of PTC Therapeutics (PTCT) in Q4 2013, closing a stake of 119,237 shares — an estimated $2.56M sold.

CR Intrinsic Investors first reported a position in PTCT in Q3 2013 and held it in 1 quarter. The position peaked at $2.56M in Q3 2013. 61 funds tracked by Wall St. Rank hold PTCT as of Q4 2013.

  • CR Intrinsic Investors reported no remaining PTC Therapeutics position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 119,237 PTC Therapeutics shares in Q4 2013, an estimated $2.56M.
  • CR Intrinsic Investors first reported a position in PTC Therapeutics in Q3 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's PTC Therapeutics position peaked at $2.56M in Q3 2013.
  • 61 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.